We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 10, 2022

Effect of Sacubitril/Valsartan vs Ramipril on Cardiovascular Events in Patients With Acute Myocardial Infarction



Additional Info

Disclosure statements are available on the authors' profiles:

The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial
Circulation 2022 Nov 02;[EPub Ahead of Print], R Mehran, PG Steg, MA Pfeffer, K Jering, B Claggett, EF Lewis, C Granger, L Køber, A Maggioni, DL Mann, JJV McMurray, JL Rouleau, SD Solomon, G Ducrocq, O Berwanger, CG De Pasquale, U Landmesser, M Petrie, DSK Leng, P van der Meer, M Lefkowitz, Y Zhou, E Braunwald

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading